|
As FDA Dawdles on Interchangeability, Expert Questions Whether It’s Doable
Companies blazing a path in the biosimilars arena likely have a long wait before their products can achieve an interchangeability designation, as the FDA admits to slow progress on that standard.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives